Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093328 | 0.87 | MAPT (0.51) | MEN1KMT2AKDM4ECNR1STS | |
| SCHEMBL30527677 | 0.84 | HDAC1 (0.45) | MEN1KMT2AUSP30KDM4EESR2 | |
| SCHEMBL25305715 | 0.84 | HDAC1 (0.45) | MEN1KMT2AUSP30KDM4EESR2 | |
| SCHEMBL13261646 | 0.81 | MEN1 (0.43) | MEN1KMT2AUSP30KDM4ECNR1 | |
| SCHEMBL1104984 | 0.80 | MEN1 (0.42) | MEN1KMT2AUSP30KDM4ECNR1 | |
| SCHEMBL2272601 | 0.80 | CACNB4 (0.49) | MEN1KMT2AUSP30ANO1ESR2 | |
| SCHEMBL20757468 | 0.79 | MEN1 (0.57) | MEN1KMT2AUSP30KDM4ESTS | |
| SCHEMBL19202529 | 0.79 | ESR2 (0.51) | MEN1KMT2AUSP30KDM4ECNR1 | |
| SCHEMBL1095073 | 0.79 | PTGDR2 (0.43) | MEN1KMT2AHSD17B10MAOAMAOB | |
| SCHEMBL25281540 | 0.79 | PDE4B (0.49) | MEN1KMT2AUSP30KDM4ECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | MEN1 4141/4885KMT2A 3314/4885USP30 2940/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | MEN1 4141/4885KMT2A 3314/4885USP30 2940/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | MEN1 4141/4885KMT2A 3314/4885USP30 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.